- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Lobe Sciences Ltd (2): Lobe Sciences appoints Goeken as chief medical officer | 1 | Stockwatch | ||
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.10. | Lobe Sciences Ltd.: Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer | 346 | ACCESS Newswire | Physician executive brings clinical development and regulatory experience in generalized anxiety disorder and sickle cell diseaseCompany also engages Independent Trading Group (ITG) to provide market-making... ► Artikel lesen | |
| 14.10. | Lobe Sciences Ltd (2): Lobe Sciences appoints Grimaldi as director | 1 | Stockwatch | ||
| 14.10. | Lobe Sciences Ltd.: Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors | 248 | ACCESS Newswire | Executive with three decades of life sciences financing and M&A experience joins the board as Lobe advances L-130 in anxiety and cluster headache and S-100 in sickle cell disease VANCOUVER, BC / ACCESS... ► Artikel lesen | |
| 08.10. | Lobe Sciences Ltd (2): Lobe Sciences to make moves in IR, PR and directorships | 1 | Stockwatch | ||
| 08.10. | Lobe Sciences Ltd.: Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth | 312 | ACCESS Newswire | Company intends to initiate independent market-making services, expanded investor and media outreach, and add board expertise in Canadian and U.S. capital markets VANCOUVER, BC / ACCESS Newswire / October... ► Artikel lesen | |
| 15.09. | Lobe Sciences Ltd.: Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit | 498 | ACCESS Newswire | ? Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16? Presentation... ► Artikel lesen | |
| 14.09. | ArcStone US Corp.: Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto | 480 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe" or the "Company") is pleased to announce its participation in... ► Artikel lesen | |
| 01.09. | Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement | 631 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F)... ► Artikel lesen | |
| 29.08. | Lobe Sciences Ltd (2): Lobe Sciences increases private placement to $2.16M | 2 | Stockwatch | ||
| 29.08. | Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement | 640 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 28.08. | Lobe Sciences Ltd (2): Lobe Sciences appoints Kideckel as CFO | 1 | Stockwatch | ||
| 28.08. | Lobe Sciences Ltd.: Lobe Sciences Expands Leadership Team with New CFO Appointment | 399 | ACCESS Newswire | Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experienceCurrent CFO, Mirza Rahimani, transitions... ► Artikel lesen | |
| 20.08. | Lobe Sciences Ltd (2): Lobe Sciences closes $2.1-million private placement | 1 | Stockwatch | ||
| 20.08. | Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement | 302 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 19.08. | Lobe Sciences reports Q3 results | 1 | Seeking Alpha | ||
| 18.08. | Lobe Sciences Ltd.: Lobe Sciences Reports Third Quarter 2026 Financial Results | 308 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic... ► Artikel lesen | |
| 13.08. | Lobe Sciences Ltd (2): Lobe Sciences arranges $2.1-million private placement | 1 | Stockwatch | ||
| 12.08. | Lobe Sciences to raise C$2.1M in private placement | 3 | Seeking Alpha | ||
| 12.08. | Lobe Sciences Ltd. Announces Non-Brokered Private Placement | 622 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe"... ► Artikel lesen |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,190 | +1,33 % | Aufsichtsratswechsel bei Puma, Margendruck bei BYD und klinische Meilensteine bei BioNxt Solutions! Unser dreifacher Check für Ihr Depot! | Der Sportartikelhersteller Puma treibt nach einem Eigentümerwechsel und dem Einstieg von Anta Sports seine strategische Neuausrichtung voran. Der chinesische Elektroautokonzern BYD schlägt sich mit... ► Artikel lesen | |
| HELUS PHARMA | 9,540 | -0,37 % | Helus Pharma Inc: Helus Pharma appoints Lawson as chair | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Deena Siblock and Conclusion of Consulting Arrangement | Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - SOL GLOBAL INVESTMENTS CORP. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB0) ("SOL Global" or the "Company") announces that Deena Siblock has resigned... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,030 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Continuance into British Columbia | Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has continued... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,008 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases | Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs TORONTO, ON / ACCESS Newswire / September 15,... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics liefert QuickStrip-Produktionslinie an die cGMP-Anlage von Callan JMB in Texas | DJ PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics liefert QuickStrip-Produktionslinie an die cGMP-Anlage von Callan JMB in Texas
Unternehmensmitteilung für den Kapitalmarkt
... ► Artikel lesen | |
| QIAGEN | 45,100 | 0,00 % | Qiagen-Aktie +6%: Lohnt der Einstieg kurz unter 46,50 €? | Die Qiagen-Aktie springt am Donnerstag auf 45,49 Euro und gewinnt im frühen Xetra-Handel über 6 Prozent. Auslöser ist ein konkretes Übernahmeangebot des schwedischen Finanzinvestors EQT von 46,50 Euro... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,500 | 0,00 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| BICARA THERAPEUTICS | 9,720 | -0,41 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,790 | +0,03 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,980 | 0,00 % | Dyne downgraded at Oppenheimer on questions over myotonic dystrophy asset | ||
| KINIKSA PHARMACEUTICALS | 95,23 | +0,05 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| RECURSION PHARMACEUTICALS | 4,350 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| PRIME MEDICINE | 5,370 | +0,19 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,220 | -0,04 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? |
LOBE SCIENCES LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,029 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.